Closing Bell: Sensex ends 572 pts lower, Nifty holds 10,600; Maruti Suzuki, RIL, Yes Bank major losers.
Benchmark indices remained under pressure throughout the session with Nifty ended just above 10,600 level, while Sensex lost 570 points.
The Sensex was down 572.28 points at 35,312.13, while Nifty was down 181.70 points at 10,601.20. About 745 shares have advanced, 1778 shares declined, and 150 shares are unchanged.
Maruti Suzuki, Tata Motors, Yes Bank, Reliance Industries and Adani Ports are the major losers on the Sensex.
HEADLINES OF THE DAY
Oil prices are trading lower after Saudi Energy Minister statement with Brent crude oil is trading around USD 61 per barrel.
RBI likely to keep policy rates unchanged for the rest of FY19: Anand Rathi.
Allahabad Bank to raise funds: The company approved raising equity capital by an amount aggregating up to Rs 3054 through preferential issue of equity shares to the Government of India.
Muthoot Finance shares fell more than 10 per cent after the asset quality deteriorated in the quarter ended September 2018.
All sectoral indices traded in the red in the afternoon with Nifty Bank, Auto, FMCG, Financial Service, FMCG, Metal and Realty falling 1-2 per cent.
Reliance Capital constitute search & selection committee for CEO.
Alembic Pharmaceuticals board meet outcome: The Board of Directors of Alembic Pharmaceuticals at its meeting held today has approved the issue of Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of up to Rs 500 crore on Private Placement basis.
Manappuram Finance will be considering a fund raising issue through NCDs on December 11, 2018.
Aurobindo Pharma extends losses: Aurobindo Pharma shares fell 5.6 percent intraday Thursday on top of 3 percent loss seen in previous session after a media report indicated that the company named in a lawsuit for selling adulterated irbesartan products.
The crucial resistance for Nifty spot is now seen at 10800 and above this 10960 Support for the immediate term is now placed at 10510 next support will be 10420.
0 comments:
Post a Comment